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The Tat protein of human immunodeficiency virus type 1 (HIV-1) is a potent trans-activator of transcription from the viral
LTR promoter. Previous mutagenesis studies have identified domains within Tat responsible for binding to its TAR RNA target
and for transcriptional activation. The minimal Tat activation domain is composed of the N-terminal 48 residues, and mutational
analyses identified a cluster of critical cysteines. The importance of four highly conserved aromatic amino acids within the
activation domain has not been thoroughly investigated. We have systematically substituted these aromatic residues (Y26,
F32, F38, Y47) of the HIV-1 LAI Tat protein with other aromatic residues (conservative mutation) or alanine (nonconservative
mutation). The activity of the mutant Tat constructs was measured in different cell lines by transfection with a LTR–CAT
reporter plasmid. The range of transcriptional activities measured for this set of Tat mutants allowed careful assessment of
the level of Tat activity required for optimal viral replication. To test this, the mutant Tat genes were introduced into the pLAI
infectious molecular clone and tested for their effect on virus replication in a T-cell line. We found that a twofold reduction
in Tat activity already affects viral replication, and no virus replication was measured for Tat mutants with less than 15%
activity. This strict correlation between Tat activity and viral replication demonstrates the importance of the Tat function to
viral fitness. Interestingly, a less pronounced replication defect was observed in primary cell types. This finding may correlate
with the frequent detection of proviruses with Tat-inactivating mutations in clinical samples. q 1997 Academic Press
INTRODUCTION which cellular proteins participate in Tat-mediated tran-
scriptional activation.
The Tat protein of human immunodeficiency virus type
On the basis of Tat mutational analyses and phyloge-
1 (HIV-1) is essential for viral replication. Full-length Tat
netic comparisons of protein sequences from different
is encoded by two exons on a spliced transcript and is HIV-1 isolates, a domain model has been proposed for
86–101 amino acids in length, depending on the viral the Tat protein (Fig. 1A) (Kuppuswamy et al., 1989). Tat
isolate. Tat is directed to the nucleus by a basic nuclear was arbitrarily divided into an acidic N-terminal domain,
localization domain and trans-activates transcription a cysteine-rich domain of 16 amino acids including 7
from the viral promoter located in the 5* long-terminal- cysteine residues, a highly conserved core domain, and a
repeat (LTR) region of the HIV-1 genome. The binding basic domain consisting of a stretch of positively charged
site for Tat in the promoter region is formed by an RNA amino acids. The C terminus of the protein spans the
stem–loop structure present at the 5* end of all HIV splice junction and is rich in glutamine residues. The
mRNAs, the trans-acting responsive (TAR) element (Berk- first coding exon of Tat (amino acids 1–72) is sufficient
hout et al., 1989; Dingwall et al., 1989). Whereas Tat binds for trans-activation of the HIV-1 promoter (Seigel et al.,
a three-nucleotide bulge in the TAR hairpin (Berkhout 1986; Hauber et al., 1989; Ruben et al., 1989; Kuppus-
and Jeang, 1989; Dingwall et al., 1990), the essential wamy et al., 1989; Garcia et al., 1988). Positively charged
TAR loop has been proposed to contribute to the trans- amino acids of the basic domain (residues 49–57) are
activation mechanism by binding of a cellular cofactor essential both for nuclear localization of the Tat protein
(Sheline et al., 1991; Wu et al., 1991). In addition, cofac- and for binding to the three-nucleotide bulge in the TAR
tors may interact with the Tat protein itself (Fridell et al., RNA hairpin. Site-directed mutagenesis studies revealed
1995; Kashanchi et al., 1994; Desai et al., 1991; Vescham- that the minimal Tat activation domain is located be-
bre et al., 1995; Zhou and Sharp, 1995; Yu et al., 1995a,b; tween residues 1 and 48 (Kuppuswamy et al., 1989; Gar-
Wu-Baer et al., 1995; Gutheil et al., 1994; Jeang et al., cia et al., 1988; Rice and Carlotti, 1990; Ruben et al.,
1993; Herrmann and Rice, 1993; Zhou and Sharp, 1996; 1989; Sadaie et al., 1988). Point mutations that cause a
Parada and Roeder, 1996). Several TAR- and Tat-binding severe Tat defect, but retain TAR RNA binding activity,
proteins have been identified, but it is currently unknown cluster in the cysteine-rich and core domains (Jeang,
1995). These domains could be involved in the binding
of cofactors. One notable feature of the Tat activation1 To whom correspondence should be addressed. Fax: (31–20)
6916531. E-mail: B. Berkhout@amc.uva.nl. domain is the cysteine-rich cluster, which has hampered
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ization/RNA-binding domain (Mujeeb et al., 1994) and an
amphipatic a-helix for the core region (Loret et al., 1991).
In a separate study with the Tat 1–37 domain fused to
the a-amylase inhibitor Tendamistat, this Tat domain was
shown to consist of an extended domain (residues 1–
21) and a coiled domain (residues 22–37) (Freund et al.,
1995). To gain further insight into the structure/function
of the HIV-1 Tat protein, we decided to analyze this pro-
tein in further detail by site-directed mutagenesis. In this
study, we focus on four conserved aromatic amino acid
residues within the activation domain (Fig. 1A). These
residues were substituted either by other aromatic amino
acids (conservative change) or by nonaromatic residues
(nonconservative change). The activity of the mutant Tat
proteins was measured by transient cotransfection of a
Tat expression vector and a LTR–CAT reporter construct
in different cell lines. This set of Tat mutants exhibited a
wide range of activities, and was subsequently intro-
duced into an infectious molecular clone to measure the
minimal Tat activity required for virus replication.
MATERIALS AND METHODS
Cells, transfection, and infection
COS, HeLa, and HLCD4-CAT cells were maintained inFIG. 1. Domain structure of the HIV-1 Tat protein and mutations
DMEM medium supplemented with 10% fetal calf serum,introduced in the activation domain. (A) The arbitrary domain structure
is that according to Kuppuswamy et al. (1989). Amino acid (aa) numbers penicillin (100 U/ml), and streptomycin (100 mg/ml).
at the domain borders are depicted, and a dotted line in the C-terminal HLCD4-CAT is a HeLa-derived cell line with an integrated
domain represents the exon border. The aa sequence of the Cys-rich
LTR–CAT construct (Ciminale et al., 1990). The SupT1 T-and core domains of HIV-1 LAI Tat is presented in single-letter code.
cell line was grown in RPMI 1640 medium containing theAromatic residues 26, 32, 38, and 47 were mutated as indicated (Y 
same supplements. Isolation of peripheral blood mono-tyrosine, F phenylalanine, W tryptophan, H histidine, A alanine,
L leucine, V valine). Two forms of mutants, Y47H and Y47A (marked nuclear cells (PBMCs), phytohemagglutinin (PHA) stimu-
with asterisks), were generated with synonymous codons. (B) Tat codon lation, and culturing were performed as described (Back
47 overlaps the Rev translation initiation codon. The Rev initiation codon
et al., 1996).AUG is underlined in the wild-type sequence. All Tat Y47 mutants
Transient transfection of adherent cells was performedexcept Y47H1 alter the Rev start codon, thereby inhibiting Rev transla-
in subconfluent 60-mm dishes by the DEAE-dextran pro-tion. This leads to efficient splicing and synthesis of the full-length 86-
aa Tat protein. tocol with cesium-purified DNA (Berkhout and Jeang,
1989). The amount of LTR-CAT plasmid was optimized
for each cell line and pTat was added in the linear range
structural studies because of oxidation and protein insol- of transcriptional activation. We used either 0.1 mg
ubility. Six of the seven cysteine residues were shown to pcDNA3–Tat and 1 mg LTR–CAT (COS cells), 1 mg of
be critically important for trans-activation activity. These pcDNA3–Tat and 1 mg LTR–CAT (HeLa), or 2 mg of
residues may be involved in binding of a divalent cation pcDNA3–Tat (HLCD4-CAT). Five million SupT1 T cells
(Frankel et al., 1988) or intrachain disulfide bond forma- were transfected transiently by electroporation with 1 mg
tion (Koken et al., 1994a). The core domain is the phyloge- of pcDNA3–Tat and 2.5 mg of LTR–CAT reporter con-
netically most conserved part of the protein and is struct (Koken et al., 1994a). SupT1 T cells and PBMC
thought to contribute to binding of Tat to the TAR element were electroporated with 1 and 2 mg, respectively, of the
(Churcher et al., 1993). HIV-1 molecular clone pLAI, and 0.5 1 106 fresh cells
To date biophysical studies have provided little detail were added after transfection to support viral replication.
on the Tat protein structure. Two structured regions were
identified by NMR: a hydrophobic core (residues 32–47) Plasmids and site-directed mutagenesis
and the C-terminal glutamine-rich domain (residues 60–
76), surrounded by the highly flexible cysteine-rich and The expression vector pcDNA3–Tat, with the HIV-1
LAI Tat gene under control of the cytomegalovirus (CMV)basic domains (Bayer et al., 1995). NMR/CD studies on
Tat peptides suggest an a-helical conformation for the immediate-early promoter, was generated by subcloning
a 3.1-kb EcoR1/Xho1 fragment from CMV-Tat (Koken etstretch of basic residues constituting the nuclear local-
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al., 1994b) into the corresponding sites in pcDNA3 (In- were prepared by three cycles of freeze/thawing (0807/
377) and CAT assays were performed by the phase-ex-vitrogen). For mutagenesis, the 0.6-kb Asp718 fragment
with the first Tat coding exon was subcloned in the traction protocol (Seed and Sheen, 1988). CA-p24 levels
were determined by ELISA on supernatant samples fromAsp718 site of M13mp18. Single-stranded phage DNA of
M13mp18Tat containing the coding (/) strand of the Tat virus-infected cell cultures (Back et al., 1996).
gene was used as template in the mutagenesis reaction
with the Bio-Rad Muta-gene kit (Kunkel, 1985). The muta- Western blotting
tions were verified by dideoxy sequencing and the mu-
Detection of Tat protein expression was carried out astant genes were recloned as Asp718 fragment in
follows. Subconfluent COS cells in 70-cm2 dishes werepcDNA3–Tat. The following (0) strand mutagenic prim-
transfected with 10 mg of the individual pcDNA3–Taters were used (mismatching nucleotides underlined):
constructs by the DEAE-dextran transfection method
(Berkhout and Jeang, 1989). Cells were washed 2 days
Y26F 5* ACACTTTTTACAGAAGCAAGTGGTACA 3*,
post-transfection with PBS and lysed in 1 ml (21 concen-
trated) SDS sample buffer. The lysate was homogenizedY26W 5* ACACTTTTTACACCAGCAAGTGGTACA 3*,
by shearing through a syringe needle (21 gauge) to re-
Y26H 5* ACACTTTTTACAGTGGCAAGTGGTACA 3*,
duce viscosity. The samples were separated by electro-
phoresis on a 20% SDS–PAA gel, which was subse-Y26A 5* ACACTTTTTACAGGCGCAAGTGGTACA 3*,
quently blotted on a nitrocellulose filter (Millipore). PAGE
F32W 5* AACTTGGCAATGCCAGCAACACTTTTT 3*,
and Western blotting were performed essentially as de-
scribed (Sambrook et al., 1989). Tat protein was detectedF32A 5* AACTTGGCAATGGGCGCAACACTTTTT 3*,
with Tat-specific mouse monoclonal antibodies and goat
F32L 5* AACTTGGCAATGGAGGCAACACTTTTT 3*,
anti-mouse alkaline phosphatase conjugate. The blots
were stained with BCIP/NBT (Sigma). The monoclonalF38Y 5* GGCTTTTGTTGTATAACAAACTTGGCA 3*,
antibodies (Nos. 2 and 4) used in the different Western
F38W 5* GGCTTTTGTTGTCCAACAAACTTGGCA 3*,
blot experiments were generously provided by Dr. Chris-
tine Debouck (Brake et al., 1990).F38A 5* GGCTTTTGTTGTAGCACAAACTTGGCA 3*,
Y47F 5* CTTCTTCCTGCCGAAGGAGATGCCTAA 3*,
RESULTS
Y47W 5* CTTCTTCCTGCCCCAGGAGATGCCTAA 3*,
Mutation of conserved aromatic residues in the HIV-1
Y47H1 5* CTTCTTCCTGCCATGGGAGATGCCTAA 3*, Tat activation domain
Y47H2 5* CTTCTTCCTGCCGTGGGAGATGCCTAA 3*, We constructed an expression vector that allows high-
level expression of the full-length HIV-1 Tat protein. TheY47A 5* CTTCTTCCTGCCGGCGGAGATGCCTAA 3*.
3.1-kb genomic DNA fragment of the LAI isolate was
cloned behind the CMV immediate-early promoter in the
The mutants Y47A2 and Y47V used in this study were
expression vector pcDNA3. The resulting pcDNA3–Tat
not designed, but were fortuitously generated in the mu-
construct (Fig. 2) efficiently expresses Tat in a variety of
tagenesis reaction with primer Y47A. Mutants F38Y and
cell types and, because of the presence of the SV40
F38A were constructed in M13mp18Tat, but repeatedly
origin of replication, produces high Tat levels in COS
resisted subcloning into pcDNA3–Tat. The reason for
cells for detection by Western blotting (see below). The
this problem is currently unknown. The LTR–CAT plas-
genomic HIV-1 sequences encode the exon-1 Tat form
mid used was described previously (pBlue-3* LTR-cat)
of 72 amino acids (aa) from unspliced transcripts, and
(Klaver and Berkhout, 1994). The HIV-1 molecular clone
splicing extends the open reading frame to 86 aa. Be-
pLAI was generously provided by Dr. Keith Peden (Peden
cause the construct also encodes both the Rev response
et al., 1991). These Tat mutations were introduced in
element (RRE) and the Rev protein, the unspliced tran-
this infectious construct by exchange of the 2.8-kb Sal1/
script is expected to represent the predominant RNA
BamH1 fragment of the pcDNA3–Tat plasmids with the
form. This pcDNA3–Tat vector was used to express mu-
corresponding fragment of pLAI.
tant Tat proteins with individual aa substitutions in the
activation domain.CAT assay and CA-p24 ELISA
Four highly conserved aromatic aa in the cysteine/
core domains were chosen as targets for mutagenesisFor CAT assays, the adherent cell types were washed
in PBS and harvested by trypsinization 3 days post- (Fig. 1A). We substituted each of these residues with two
alternative aromatic residues (conservative mutation) ortransfection. (Verhoef et al., 1996). SupT1 cells were col-
lected by centrifugation, washed with PBS, and resus- alanine (nonconservative mutation). In addition, some
mutants were generated on the basis of variation ob-pended in 200 ml of 0.25 M Tris–HCl (pH 8.0). Cell lysates
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FIG. 2. Schematic of the Tat expression vector pcDNA3–Tat. Shown are the vector-derived Cytomegalovirus (CMV) immediate-early promoter
(transcription start site is marked by an arrow) and the polyadenylation signal of the bovine growth hormone gene (BGHpA). Sal1 and Xho1 restriction
sites denote the borders of the subgenomic HIV-1 LAI insert. Tat and T  first and second coding exons of Tat; R and Rev  first and second
coding exons of Rev; N  truncated Nef open reading frame. The splicing signals (SD and SA) and the Rev response element (RRE) are indicated.
served at these positions in natural HIV and SIV isolates A strict correlation between Tat activity and viral
replication capacity[e.g., Y26H, F32L, Y47H (Myers et al., 1994)]. Thus, the
tyrosine residue at position 26 was replaced by phenylal-
The activity of the Tat mutants was first tested in co-
anine (Y26F), tryptophan (Y26W), alanine (Y26A), and his-
transfections with an LTR–CAT reporter plasmid in differ-
tidine (Y26H). A similar set of mutants were generated
ent cell lines. The results presented in Fig. 5 represent
for phenylalanine at position 32 and tryptophan at posi-
the mean values of three to six independent transfections,
tion 47. Please note that two of the Y47 mutants were and the activity of the wild-type Tat protein was set at
generated in duplicate with alternative, synonymous co- 100% for each cell type. In general, similar results were
dons (Y47H1/Y47H2 and Y47A1/Y47A2). The phenylala- obtained for all four cell types tested. We therefore refer
nine residue at position 38 was replaced by tryptophan mainly to the results obtained in the T-cell line SupT1.
(F38W). The conservative mutants Y26F and Y26W, as well as
Transient transfections in COS cells were performed the natural variant Y26H, demonstrated approximately full
to analyze the stability of the mutant Tat proteins. Cell activity in SupT1 cells (79–103%). The Y26H mutant
lysates were prepared and separated by SDS–PAGE,
blotted on nitrocellulose membranes, and stained with a
Tat-specific monoclonal antibody (Fig. 3). The expression
level of all mutant proteins was comparable to that of
wild-type Tat. As expected, wild-type Tat and the Y26,
F32, and F38 mutants were expressed predominantly in
the unspliced exon-1 form (72 aa, 14 kDa). In contrast,
all Y47 mutants except Y47H1 shift the expression toward
the spliced exon 1 / 2 form (86 aa, 17 kDa). One particu-
lar feature of Tat codon 47 (UAU) is that it overlaps the
start codon of the Rev open reading frame (AUG). Muta-
tion of Tat codon 47 is therefore expected to affect Rev
translation by changing either the initiation codon or the
upstream Kozak consensus sequence (Kozak, 1989). The
sequences around the Rev start codon of all Tat codon
47 variants are listed in Fig. 1B, and the effect on Rev
translation is indicated. Splicing will be efficient in the
absence of Rev synthesis, leading to increased synthesis
of the 2-exon 86-aa Tat protein. Consistent with these
predictions, all Y47 mutants except Y47H1 affect Rev
translation. However, no gross differences in the steady-
state Tat protein levels were measured. Because subse-
FIG. 3. Wild-type and mutant Tat proteins are stably expressed in
quent Tat trans-activation assays were performed in the COS cells. Western blot analysis of Tat protein expression in transiently
SupT1 T-cell line, we tested expression levels for a sub- transfected COS cells. The wild-type Tat (WT) is shown next to a mock-
transfected sample (0). Lane M contains marker proteins (molecularset of the Tat proteins in these cells (Fig. 4). Consistent
mass in kilodaltons). The set of Tat mutants at positions Y26 and F32with the results in COS cells, no major differences were
in A was stained with Ab 2. The blot in B was probed with Ab 4 and
measured in the intracellular protein levels, and the contains samples of the Tat mutants at position Y47, the single F38W
Y47W mutant with the Rev defect did not produce the mutant, and a Q72stop variant with a premature stop codon to yield a
Tat protein of 71 amino acids (Verhoef and Berkhout, in preparation).exon 1 form of the Tat protein.
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mutants exhibited some decrease in replication capacity.
No virus production was measured for Y26A, F32A, and
all codon 47 mutants except Y47H1. We do not discuss
these codon 47 mutants further because their replication
defect is in part due to mutation of the Rev start codon
(Fig. 1B, with the exception of mutant Y47H1). These
results reveal a strict correlation between the Tat tran-
scriptional activity as measured in transient LTR-CAT
assays and the replication potential of the mutant vi-
ruses. The ranking order of the replication potential of
these viruses is as follows, with the relative LTR-CATFIG. 4. Five million SupT1 T cells were electroporated with 50 mg of
activity in SupT1 cells shown within parentheses: wildthe individual Tat plasmids, and harvested on Day 2 post-transfection.
The immunoblot was stained with mAb 4. See Fig. 3 for further details. type (100%)  Y26H (79%)  Y26F (103%)  Y26W (86%)
@ F32W (74%), F32L (47%)  Y47H1 (37%)  F38W (42%)
@ Y26A (7%), F32A (0%). The correlation coefficient for
dropped to about 50% activity in the other cell types and Tat activity and viral replication was measured on Day 5
the nonconservative Y26A mutant was severely defective post-transfection, excluding the Rev0 viruses. There was
with less than 10% activity. The one conservative mutant a linear correlation between Tat activity and the log of
tested at position F32W retained considerable activity virus production, with an R2 value of 0.82 (P  0.0005).
(74%). The natural variation F32L was also partially active Several studies have reported considerable replication
(47%), but F32A was completely inactive (1%). The singular of Tat-mutated viruses in a variety of cell types (see Dis-
mutant at position F38W was partially active (42%). Simi- cussion). We therefore tested whether the replication-
larly, all codon 47 mutants displayed reduced activity in impaired mutants Y26A and F38W could be rescued by
SupT1 cells (10–47%), although the conservative mutant cellular activation with phorbol myristate acetate (PMA)
Y47F was slightly better than the other mutants, including and/or PHA, but no improved replication was observed
Y47W, in the other cell types. In contrast to the other (data not shown). We also tested the four Y26 mutants
aromatic positions tested, Y47 replacement by alanine in primary cells. PBMCs were electroporated with the
does not fully inactivate the protein. wild-type and mutant constructs and virus replication
In general, similar results were obtained with this set was monitored for up to 14 days (Fig. 7). In general,
of Tat mutants in the SupT1 T-cell versus the non-T-cell less severe replication defects were observed in PBMCs
lines HeLa and COS. However, the Tat defects scored compared with the SupT1 T-cell line. For instance, we
in the latter cell type were generally less severe. For measured a low level of virus replication for the Y26A
instance, all Y47 mutants were active in COS cells (77 – mutant, which is absolutely replication-impaired in SupT1
129%), but significant defects were measured in HeLa cells. These results suggest that the requirement for ac-
(27–66%) and SupT1 (10 –47%) cells. Furthermore, the tive Tat protein is less stringent in primary cell types.
most defective Tat mutants in SupT1 and HeLa cells
(Y26A and F32A, less than 10% activity) show substantial DISCUSSION
activity in COS cells (18–22%). To test the activity of the
mutant Tat proteins on a chromosomally integrated LTR – A diversity of transcriptional defects were observed
for Tat variants mutated at aromatic residues within theCAT reporter, we also transfected HLCD4-CAT cells. No
significant differences were measured in comparison activation domain. The combined results of transient
LTR–CAT and infectivity assays indicate that Tat residuewith the parental HeLa cells (Fig. 5).
We next tested the complete set of Tat mutants in viral Y26 is relatively insensitive to substitution by other aro-
matic amino acids, but introduction of an alanine residuereplication studies to determine the level of Tat activity
required for virus replication. Furthermore, any discrep- did abolish both the Tat function and virus replication.
The Y26H mutant demonstrates suboptimal activity (79%ancies between the two assay systems may be indicative
of nontranscriptional roles of Tat in the replication cycle. activity in SupT1 cells, see Fig. 4) and supported signifi-
cant levels of virus replication. This finding is consistentThe SupT1 T cell was transfected with the individual
proviral constructs and viral replication was monitored with the natural variation at this position in 56 HIV-1
isolates (51 Y, 4 H, 1 F). Significantly reduced replicationby measuring CA-p24 antigen production in the culture
medium (Fig. 6). Compared with the wild-type virus, all was measured for the Y26F and Y26W mutants, even
FIG. 5. Transcriptional activity of the wild-type and mutant Tat proteins. Cotransfections were performed with a LTR–CAT reporter construct in
SupT1, COS, HeLa, and HLCD4-CAT cells. The trans-activation activity obtained with wild-type Tat was set at 100% for every cell type tested. The
actual promoter induction levels with wild-type Tat were approximately 100-fold (COS), 20-fold (HeLa), 10-fold (HLCD4-CAT), and 300-fold (SupT1).
The results presented are averages of three to six independent transfection experiments.
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for virus replication. We found that a small reduction in
Tat activity does already affect viral infectivity (e.g., F32L
and F38W, 47 and 42% Tat activity in SupT1 cells, respec-
tively), and no viral replication was measured in the
SupT1 T-cell line for Tat mutants with less than 10%
activity (e.g., Y26A). In general, no gross discrepancies
were apparent between the transient transcription and
viral replication assays, but the mutants Y26F, Y26W, and
F32W exhibited a more severe replication defect than
was expected on the basis of their transcriptional activity
in SupT1 cells. These differences may be indicative of
an additional role of the Tat protein in virus replication
(Huang et al., 1994), but further experimentation is re-
quired to elaborate on this point.
We also tested the Tat-mutated viruses for their ability
FIG. 6. Replication kinetics of Tat-mutated HIV-1 viruses. The SupT1 to replicate in primary cell types. Replication defects
T-cell line was transfected with 1 mg of the wild-type and mutant con- were also apparent in PBMCs, albeit less dramatic than
structs, and virus production was measured in the culture supernatant
in the transformed T-cell line SupT1. Cellular activationby CA-p24 ELISA several days post-transfection. The culture was split
by PMA and/or PHA did not change the replication poten-on Days 5 and 7 post-transfection, causing a slight drop in CA-p24
values. No replicating virus was recovered from transfections with mu- tial of Tat-mutated viruses. Several studies reported con-
tants Y26A, F32A, and all Rev0 codon 47 mutants; all these samples siderable replication of Tat-mutant viruses in a variety of
are marked with crosses. cell types (Dimitrov et al., 1993; Chang and Zhang, 1995;
Zhu et al., 1996; Luznik et al., 1995; Duan et al., 1994).
Thus, it appears that HIV-1 replication is dependent pri-though the Tat activity in transient transcription assays
reached levels (103 and 86%) at least equal to that of the marily on the Tat function in transformed T-cell lines,
which may resemble mature, peripheral T cells in HIV-Y26H mutant. The reduced replication capacity of these
two Tat mutants correlates with the natural variation at infected individuals. The observation that Tat is most
critical in transformed T-cell lines is diametrical to thethis position; only one natural HIV-1 isolate has a phenyl-
alanine (F) at position 26 and no isolates have been situation described for the so-called accessory HIV-1
gene products (Nef, Vif, VpR, VpU), which are requiredreported with a tryptophan (W) at this position.
Significant Tat activity was retained on introduction of predominantly in primary cell types (reviewed by Subra-
manian and Cohen, 1994). The relative unimportance ofa conservative mutation at position 32 (F32W, 74% activity
in SupT1 cells), but a rather severe effect on viral replica- Tat in certain cell types may explain the abundance of
Tat-mutated proviruses in clinical samples (Meyerhanstion was measured. The nonconservative F32L mutation
did partially reduce Tat activity (47%) and virus replica- et al., 1989; Sabino et al., 1994).
Previous studies with Tat mutants containing eithertion. Both amino acid substitutions are present in a signif-
icant number of the 56 natural HIV isolates (25 F, 20 Y, truncations or substitutions in the basic domain identified
a trans-dominant negative phenotype (Pearson et al.,7 L, 4 W). This result suggests that suboptimal Tat func-
tion is allowed in vivo. Alternatively, one cannot exclude 1990; Modesti et al., 1991; Orsini and Debouck, 1996).
the possibility that compensatory, second-site mutations
are present within the Tat protein of these isolates. A
conservative mutation at Tat position 38 (F38W) demon-
strated reduced Tat activity (42%) and a significant delay
in virus replication. Consistent with this result, residue
F38 is absolutely conserved in natural HIV-1 isolates. We
measured considerable Tat activity for all Y47 mutants,
but no replicating virus was recovered with the exception
of the Y47H1 mutant. This discrepancy is explained by
the fact that mutations in Tat codon 47 also affect the
overlapping start codon of the Rev gene. In fact, Y47H1
is the only mutant at position 47 that maintains the AUG
start codon (Fig. 1B). This additional sequence require-
ment does explain the nearly absolute conservation of
FIG. 7. Replication kinetics of Y26-mutated HIV-1 variants in primary
this Tat residue in 56 natural isolates (55 Y, 1 H). cells. PBMCs were transfected with 2 mg of the wild-type and mutant
The set of Tat activation domain mutants allowed us constructs and virus production was measured in the culture superna-
tant by CA-p24 ELISA several days post-transfection.to accurately determine the level of Tat activity required
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Ciminale, V., Felber, B. K., Campbell, M., and Pavlakis, G. N. (1990). ASuch proteins have low intrinsic activity, but are power-
bioassay for HIV-1 based on Env–CD4 interaction. AIDS Res. Hum.fully capable of inhibiting the wild-type Tat protein func-
Retroviruses 6, 1281–1287.
tion in trans. We therefore tested all Tat mutants with Desai, K., Loewenstein, P. M., and Green, M. (1991). Isolation of a
less than 50% transcriptional activity in cotransfections cellular protein that binds to the human immunodeficiency virus Tat
with equimolar amounts of wild-type Tat, but none of the protein and can potentiate transactivation of the viral promoter. Proc.
Natl. Acad. Sci. USA 88, 8875–8879.mutants displayed a trans-dominant negative phenotype
Dimitrov, D. S., Willey, R. L., Sato, H., Chang, L.-J., Blumenthal, R., and(results not shown).
Martin, M. A. (1993). Quantitation of human immunodeficiency virusThe Tat mutants provide a nice set of reagents with a
type 1 infection kinetics. J. Virol. 67, 2182–2190.
diverse activity spectrum that can be used for further Dingwall, C., Ernberg, I., Gait, M. J., Green, S. M., Heaphy, S., Karn, J.,
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